利妥昔单抗联合低剂量环磷酰胺和泼尼松治疗原发性膜性肾病:扩展随访病例系列
该单中心回顾性病例系列纳入60例原发性膜性肾病患者,采用利妥昔单抗联合初始短程低剂量口服环磷酰胺及快速减量泼尼松治疗。中位随访38个月,全部患者达到部分缓解,2年时83%达到完全缓解,抗PLA2R抗体阳性者免疫学缓解迅速,B细胞耗竭期间无复发,安全性可接受。
要点
- 联合治疗下全部患者达到部分缓解,2年时83%达到完全缓解。
- 抗PLA2R抗体阳性患者3个月和6个月免疫学缓解率分别为86%和100%。
- B细胞耗竭期间无复发,B细胞重建后2年复发率为10%。
核心结论
- 联合治疗使所有原发性膜性肾病患者达到部分缓解,多数获得持久完全缓解,安全性可接受。
研究设计与样本
- 单中心回顾性病例系列,纳入60例连续接受联合治疗的原发性膜性肾病患者。
主要发现
- 中位随访38个月(IQR 25-62),全部患者在中位3.4个月达到部分缓解(UPCR<3 g/g且较基线下降50%)。
- 治疗启动后2年内83%达到完全缓解(UPCR<0.3 g/g),中位完全缓解时间12.4个月。
- 抗PLA2R抗体阳性患者(n=29)在3个月和6个月免疫学缓解率(抗PLA2R滴度<14 RU/mL)分别为86%和100%。
- 治疗1年后中位UPCR从8.4 g/g(IQR 5.0-10.7)降至0.3 g/g(IQR 0.2-0.8)(P<0.001)。
- B细胞耗竭期间无复发;末次利妥昔单抗后B细胞重建起2年时10%患者复发;228患者年随访中共18例严重不良事件,1例非治疗相关死亡,1例进展至肾衰竭需肾脏替代治疗。
临床怎么用
- 对于原发性膜性肾病,可考虑利妥昔单抗联合初始短程低剂量环磷酰胺和快速减量泼尼松方案。
- 治疗中应监测抗PLA2R抗体滴度和B细胞水平以评估免疫学缓解和复发风险。
局限性
- 缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: B-cell depletion with rituximab has emerged as a first-line therapy for primary membranous nephropathy (MN). However, most patients do not achieve complete remission with rituximab monotherapy. In this case series, we report longer-term remission and relapse rates, anti-phospholipase A2 receptor (PLA2R) antibody levels, B-cell levels, and serious adverse events in patients with primary MN who received rituximab combined with an initial short course of low-dose oral cyclophosphamide and a course of rapidly tapered prednisone. STUDY DESIGN: Single-center retrospective case series. SETTING & PARTICIPANTS: 60 consecutive patients with primary MN treated with the combination of rituximab, low-dose cyclophosphamide, and prednisone at the Vasculitis and Glomerulonephritis Center at the Massachusetts General Hospital. FINDINGS: After treatment initiation, median follow-up was 38 (interquartile range [IQR], 25-62) months; 100% of patients achieved partial remission, defined as a urinary protein-creatinine ratio (UPCR) < 3 g/g and a 50% reduction from baseline, at a median of 3.4 months. By 2 years after treatment initiation, 83% achieved complete remission, defined as a UPCR < 0.3 g/g. The median time to complete remission was 12.4 months. Immunologic remission (defined by an anti-PLA2R titer < 14 RU/mL) was achieved by 86% and 100% of anti-PLA2R seropositive patients (n = 29) at 3 and 6 months, respectively, after treatment initiation. After 1 year, the median UPCR fell from 8.4 (IQR, 5.0-10.7) to 0.3 (IQR, 0.2-0.8) g/g (P < 0.001). No patient relapsed throughout the duration of B-cell depletion. Relapse occurred in 10% of patients at 2 years after the onset of B-cell reconstitution following the last rituximab dose. Over a combined follow-up time of 228 patient-years, 18 serious adverse events occurred. One death occurred unrelated to treatment or primary MN, and 1 patient progressed to kidney failure requiring kidney replacement therapy. LIMITATIONS: Absence of a comparison group. CONCLUSIONS: All patients with primary MN treated with combination therapy achieved partial remission and most achieved a durable complete remission with an acceptable safety profile.
引用
- Zonozi R, Laliberte K, Huizenga NR, et al. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up. Am J Kidney Dis. 2021. PMID: 34174365. doi:10.1053/j.ajkd.2021.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。